| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CLPT.2004.10.002 |
| P698 | PubMed publication ID | 15735612 |
| P2093 | author name string | Naga Chalasani | |
| Suthat Liangpunsakul | |||
| J Christopher Gorski | |||
| Mitchell A Hamman | |||
| Stephen D Hall | |||
| Ying-Hong Wang | |||
| Todd Skaar | |||
| Dhanashri Kolwankar | |||
| Million Arefayene | |||
| Amar G Pinto | |||
| P2860 | cites work | Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state | Q39780438 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clarithromycin | Q118551 |
| antibiotic | Q12187 | ||
| P304 | page(s) | 178-188 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression | |
| P478 | volume | 77 |
| Q46511442 | Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report |
| Q45907681 | Antimalarial interaction of quinine and quinidine with clarithromycin. |
| Q37359687 | Association of genotypes of the CYP3A cluster with midazolam disposition in vivo |
| Q35322473 | Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma |
| Q47985538 | Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis- infected Swiss mice |
| Q43246296 | Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine |
| Q50586527 | Collagenous colitis appeared after 6-year administration of lansoprazole. |
| Q37023996 | Drugs as CYP3A probes, inducers, and inhibitors |
| Q37017426 | Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. |
| Q38625769 | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers |
| Q36580598 | Emerging drugs to replace current leaders in first-line therapy for breast cancer |
| Q36536037 | Interaction between midazolam and clarithromycin in the elderly |
| Q36985043 | Intestinal permeability and its relevance for absorption and elimination |
| Q34510611 | Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults |
| Q37247655 | Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration |
| Q36413309 | Numerical analysis of time dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting |
| Q37205954 | Pharmacogenetics of analgesics: toward the individualization of prescription |
| Q33613354 | Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin |
| Q39348794 | Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs |
| Q37016344 | Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin |
| Q37319907 | Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry |
| Q92626380 | The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies |
| Q93054280 | The gut microbiome: an orchestrator of xenobiotic metabolism |
Search more.